Laurus Labs Ltd
Laurus Labs Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
API and formulation segments expected to grow significantly in FY’28, with some growth in FY’27 due to new capacities and validations. FY’27 and FY’28 expected growth: - Significant growth anticipated in API and formulations, especially FY’28 due to new capacities and generic API validation. - ARV segment expected stable in the Rs.
From Laurus Labs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- API and formulation segments expected to grow significantly in FY’28, with some growth in FY’27 due to new capacities and validations. (Page 21)
- ARV segment revenues expected to remain in the range of Rs. 2,500 to 3,000 crores. (Page 21)
- Generic API business growth viewed as very sustainable; FDF business growth also expected to be sustainable due to new capacities and volume gains. (Pages 15, 21)
- CDMO business reported 50% growth in 9 months FY’26; expects continued healthy growth in Q4 FY’26 and qualitative growth in FY’27 driven mainly by commercial supplies. (Pages 12, 14)
- Non-ARV formulations expected to sustain growth supported by additional capacities for CMO partners in Europe and new launches in North America. (Page 19)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New greenfield CAPEX of 500 acres in Atchutapuram: land allotment expected in Q4 FY'26; CAPEX to start in second half of FY'27; qualification and validation expected two years later (around FY'29).
- Joint venture with Krka Pharma: Phase-1 includes 3 billion solid oral tablet capacity and 100 million potent tablet capacity; Phase-1 expected completion by mid-2027; Phase-2 to add 5 billion solid oral tablet capacity.
- Peptide CDMO commercial manufacturing facility: qualification expected during calendar year 2026; integrated capacity being created including amino acids and peptide processing.
- ADC (antibody drug conjugates) GMP facility: $25 million allocated for construction; no meaningful revenue expected in next two years; investments ongoing in both CAPEX and OPEX.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not provide explicit details on the current or expected order book or pending orders for Laurus Labs Limited.
- However, it's mentioned that the CDMO business has strong recurring business from existing long-term customer relationships and a healthy pipeline with a well-balanced mix of big pharma, mid-, and small-sized biotechs.
- The company supplies multiple commercial molecules and is investing in capacity expansion, including peptides and advanced technologies.
- For human health CDMO, several programs with partners are ongoing with commercial supplies.
- Crop science CDMO products have been commercialized with meaningful supply expected in 1-2 years.
2 more points management made on order book & pipeline
Laurus Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.8K Cr, net profit ₹282 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Laurus Labs Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Laurus Labs Ltd Q3 FY26 results?
API and formulation segments expected to grow significantly in FY’28, with some growth in FY’27 due to new capacities and validations. FY’27 and FY’28 expected growth: - Significant growth anticipated in API and formulations, especially FY’28 due to new capacities and generic API validation. - ARV segment expected stable in the Rs.
What is Laurus Labs Ltd share price analysis?
Laurus Labs Ltd currently shows a neutral. The stock trades at a P/E of 88.3 with a market cap of ₹96,570 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laurus Labs Ltd planning capital expenditure?
New greenfield CAPEX of 500 acres in Atchutapuram: land allotment expected in Q4 FY'26; CAPEX to start in second half of FY'27; qualification and validation expected two years later (around FY'29).
Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.